LIQ861 Inhaled Treprostinil ( DrugBank: Treprostinil )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03992755 (ClinicalTrials.gov)	July 18, 2019	5/6/2019	Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil	A Global, Open-Label Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Inhaled LIQ861 (Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients	Primary Pulmonary Hypertension	Drug: LIQ861 Inhaled Treprostinil	Liquidia Technologies, Inc.	Nuventra, Inc.	Active, not recruiting	18 Years	N/A	All	92	Phase 3	United States
2	NCT03399604 (ClinicalTrials.gov)	January 2, 2018	3/1/2018	Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil	A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients	Primary Pulmonary Hypertension	Drug: LIQ861 Inhaled Treprostinil	Liquidia Technologies, Inc.	Nuventra, Inc.	Completed	18 Years	N/A	All	121	Phase 3	United States